OmniSeq

OmniSeq Corporation, established in 2015 and headquartered in Buffalo, New York, is committed to finding the right drug or trial for every cancer patient, providing doctors and their patients with the most actionable tumor analysis information. Additionally, it offers testing methods approved by New York State CLEP, including OmniSeq's 144-gene NGS assay, which covers nearly all known genetic alterations associated with FDA-approved targeted therapies or genotype-directed clinical trials.